Your search for ‘Smart & Biggar’ returned 2,497 results

The rug has been pulled out from under key patent rights of diagnostic companies and research institutions.

On April 27, 2015 the Canadian federal government announced that Canada would be signing onto the World Intellectual Property Organization's Marrakesh Treaty to Facilitate Access to Published Works for Persons Who Are Blind, Visually Impaired, or Otherwise Print Disabled.

Notwithstanding the somewhat surprising outcome of the Brexit vote, there is no reason to panic.

Major amendments were implemented to Canada's Trademarks Act on June 17, 2019 that impact everything from filing and oppositions to registration terms and renewal procedures.

On June 29, 2015, CIPO publicly released a brief Patent Notice to Examiners regarding examination of medical diagnostic methods.

As promised, the Canadian Intellectual Property Office has just released information on the proposed new fees that will apply when amendments to the Trademarks Act are put into effect.

Trade-mark opposition proceedings in Canada are decided at first instance by a specialized tribunal known as the Trade-marks Opposition Board ("Opposition Board").

The CanExport Innovation program, administered by the Global Affairs Canada's Trade Commissioner Service, helps Canadian organizations pursue collaborative research and development (R&D) agreements...

Most third party challenges to patentability occur in front of national or regional patent offices. WIPO recently released a summary of data regarding the extent to which third parties are challenging

Occasionally, results of litigation seems so surprising that you wonder if there has to be more to the case than what the decision discloses.

McCartney & Lennon, Jobs & Wozniak, Watson & Crick. We are all looking for synergistic collaborations. In life sciences, some of those collaborations may be with your employees, independent contractors or corporate research partners.

The provisions relating to the customs "Request for Assistance" procedure in Bill C-8, the Combating Counterfeit Products Act, came into force on January 1, 2015.

New drugs require a huge amount of innovation, time, capital and risk to get to market. Nobody should begrudge a drug company for seeking strong patent protection.

Fair dealing in educational contexts has been a hot issue in Canada. Canadian copyright lawyers and scholars have been watching two cases involving Canadian universities that have been making...

On May 15, 2020, Manson J. of the Federal Court dismissed two actions brought by Biogen under the Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations) alleging infringement...

On December 22, 2020, the Federal Court issued its decision holding that section 8.2 of the Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations)...

The Federal Court of Appeal (FCA) dismissed an appeal by Biogen and a cross-appeal by Taro from a decision of the Federal Court (see our previous article) dismissing two actions...